Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo, Viatris
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic. The companies announced the settlement in a joint filing on Friday made with the U.
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the validity of the Danish drugmaker’s semaglutide patents.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according
1d
on MSN
Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments
We recently published a list of 8 Stocks Under $20 To Invest In Now. In this article, we are going to take a look at where ...
3d
Viatris 2023 Sustainability Report: Reducing Packaging Material
NORTHAMPTON, MA / ACCESSWIRE / October 10, 2024 / Viatris is continuously looking for ways to reduce the volume and types of ...
Zawya
1d
Viatris Middle East collaborate with ‘mentl’
DUBAI – As World Mental Health Day is marked around the globe, a new collaboration between the advocacy platform ‘mentl’, and ...
5d
on MSN
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?
We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy. In this piece, we will look at where Viatris Inc.
5d
Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts
Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...
5d
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety ...
Morningstar
6d
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
PITTSBURGH, Oct. 8, 2024 /PRNewswire/ --
Viatris
Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024.
Khaleej Times on MSN
4d
UAE: New mental health podcast to 'tear away silence' on stigma, wellness in workplace
A new mental health podcast will be coming up in the UAE soon, creating a unique advocacy platform committed to tackling the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
Ozempic
VTRS
Feedback